NCPE course “Update on Pharmacoeconomics in the Irish Healthcare Setting" will take place on 6th & 7th May 2020 in Dublin Castle. We are now taking bookings.
The NCPE recommends that patisiran (Onpattro®) is not considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments
The NCPE recommend that axicabtagene ciloleucel (Yescarta®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.*